Bryan Cho-Wing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bryan Cho-Wing Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ada L.Y. Law
Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
1 shared publication - Anna Tai
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China
1 shared publication - Cynthia S. Y. Yeung
Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China
1 shared publication - Gerry Gin Wai Kwok
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
1 shared publication Hon Wai Cheng
Medical Palliative Medicine Team, Department of Medicine and Geriatric, Tuen Mun Hospital, Tuen Mun, Hong Kong
1 shared publication- Jeffrey Sum Lung Wong
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
1 shared publication
Latest Publications
- Open Access
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
(1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.
Open AccessThe Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
(1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2018 and September 2020 in Hong Kong. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), and adverse events (AE) were assessed. (3) Results: Overall, 42 patients were included. Approximately 83.3% had Child-Pugh A cirrhosis. About 64.3% received cabozantinib as a single agent, and the remaining 35.7% received cabozantinib as an add-on to immune checkpoint inhibitors (ICIs). For single-agent patients, the median follow-up was 6.7 months. The ORR was 3.7%, DCR was 44.4%, and the median OS was 8.28 months. About 74.1% of patients experienced any AEs with 7.4% having grade ≥3 AEs. Among patients who received prior ICIs (n = 16), the ORR was 6.3%, and the median OS was 8.28 months. An exploratory analysis of patients who received cabozantinib as an add-on to ICIs showed an ORR of 6.7% and a median OS of 15.1 months, with 73.3% having any AE and 13.3% having grade ≥3 AEs. (4) Conclusions: Cabozantinib had good anti-tumor activity, survival benefits, and acceptable tolerability in real-life aHCC patients.
- 1 July 2018
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 7 (3) , 365-367
Embracing the setting sun: provision of palliative care via a collaborative model between hospital and community for patients with intellectual disabilities
Palliative care (PC) evolved from taking care of terminal cancer patients to modern concept of early integration into disease trajectories of patients with life limiting cancer and non-cancer diseases (1).
- 1 July 2018
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 7 (3) , 365-367
Embracing the setting sun: provision of palliative care via a collaborative model between hospital and community for patients with intellectual disabilities
Palliative care (PC) evolved from taking care of terminal cancer patients to modern concept of early integration into disease trajectories of patients with life limiting cancer and non-cancer diseases (1).